^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Yinuokai (orelabrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Prospective, multicenter phase II clinical study of orelabrutinib combined with immunochemotherapy in the treatment of newly treated high-risk diffuse large B-cell lymphoma

    Excerpt:
    ...One of the following conditions must be met to be included in the study: (1) The longest diameter of the mass assessed by CT or PET/CT is >=10 cm; (2) International Prognostic Index (IPI) >= 2 points; (3) There are more than 2 extranodal lesions; (4) Involvement of the central nervous system; (5) Secondary to the second tumor or combined with the second tumor; (6) Genetic abnormalities or molecular biological abnormalities with known poor prognosis, such as P53 gene mutation, MYD88/CD79B mutation, c-MYC/BCL2 double expression, c-MYC/BCL-2/BCL-6 double strike or triple strike; (7) CNS-IPI score >= 2 points; 5. ...
    Trial ID:
    ChiCTR2100053805
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASH 2023
    Title:

    Orelabrutinib Plus R-CHOP Regimen in Treatment-Naïve Patients with TP53-Mutated Diffuse Large B-Cell Lymphoma (DLBCL)

    Published date:
    11/02/2023
    Excerpt:
    These data supported that OR-CHOP-based regimens had favorable anti-tumor activity and manageable safety profile in pts with TP53-mutated DLBCL.
    Secondary therapy:
    R-CHOP
    DOI:
    https://doi.org/10.1182/blood-2023-177563